Symbiomics completes Series A funding round led by Corteva to advance next-generation biologicals

Symbiomics, a biotechnology company that develops high-performance biological products for agriculture, on Wednesday announced the completion of its Series A funding round to scale its operations, accelerate the development of novel products, and expand its commercial partnerships. The round is led by Corteva Agriscience through its investment platform, Corteva Catalyst, launched in mid-2024. In addition to the multinational, the Series A round includes investments from Arar Capital, Cazanga, MOV Investimentos, and The Yield Lab Latam.

The Brazilian company is the first to receive an investment from Corteva Catalyst in the country. ″Corteva’s investment represents an important recognition of Symbiomics as a company committed to developing innovative technologies for agribusiness,″ said Rafael de Souza, co-founder and CEO of the company. ″More than that, it is a significant step toward a more sustainable agriculture. The Series A funding will allow us to accelerate our developments and strengthen partnerships across the sector,″ he added.

Symbiomics’ proprietary platform enables the analysis of thousands of microorganisms in search of the most robust strains, with greater efficiency and precision than traditional methodologies. It also incorporates gene editing and molecular discovery technologies, main drivers for the next generation of biological products. Targeting a biologicals market expected to reach US$ 3.1 billion by 2030, Corteva Catalyst is making its first investment in Brazil by backing Symbiomics’ ability to deliver remarkably novel solutions.

Founded in 2021 and initially supported by Vesper Biotechnologies, the Brazilian biotech had already raised R$ 15 million in funding from Arar Capital, Cazanga, Ecoa Capital, MOV Investimentos, and The Yield Lab Latam. The funding allowed Symbiomics to conduct its first proof-of-concept studies, grow its team, open its proprietary laboratory, and build out its development platform for biologicals. ″With the Series A, we’ve reached a new stage globally, solidifying Symbiomics as one of the most leading innovators in agribusiness. This growth will increase our capacity to create innovative biological products, reach new partners, and deliver our solutions to farmers,″ explains Jader Armanhi, co-founder and COO of Symbiomics.

Symbiomics has established partnerships with several companies in the agricultural sector to co-develop innovative biological solutions. The first products resulting from these collaborations are already in the testing phase, with market launch expected within the next three years.

Show your technologies and expertise in the upcoming 2025 Biologicals Special